|
JPH09504000A
(ja)
*
|
1993-08-11 |
1997-04-22 |
ジェナー テクノロジーズ |
前立腺癌ワクチン
|
|
US20010036928A1
(en)
*
|
1996-04-22 |
2001-11-01 |
Chamberlain Ronald S. |
Heterologous boosting immunizations
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
US7148035B1
(en)
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
EP1152060B1
(en)
*
|
1998-11-18 |
2015-04-15 |
Oxford Biomedica (UK) Limited |
5T4 tumour-associated antigen for use in tumour immunotherapy
|
|
ATE361988T1
(de)
*
|
1998-12-09 |
2007-06-15 |
Us Gov Health & Human Serv |
Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden
|
|
EP1865065A1
(en)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
ATE369895T1
(de)
*
|
2002-04-09 |
2007-09-15 |
Sanofi Pasteur Ltd |
Modifizierte cea nucleinsäure und expressionsvektoren
|
|
JP2007502602A
(ja)
*
|
2003-08-21 |
2007-02-15 |
バイラックス・ディベロップメント・プロプライエタリー・リミテッド |
前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター
|
|
US8562970B2
(en)
*
|
2003-10-08 |
2013-10-22 |
Sanofi Pasteur Limited |
Modified CEA/B7 vector
|
|
AU2004289368B2
(en)
|
2003-11-12 |
2010-08-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Custom vectors for treating and preventing pancreatic cancer
|
|
ES2476990T3
(es)
*
|
2003-11-12 |
2014-07-15 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sistema para tratar y prevenir cáncer de mama
|
|
CN102281892A
(zh)
|
2009-01-13 |
2011-12-14 |
特朗斯吉有限公司 |
酿酒酵母线粒体核酸级分用于免疫刺激的用途
|
|
EP2382474B1
(en)
|
2009-01-20 |
2015-03-04 |
Transgene SA |
Soluble icam-1 as biomarker for prediction of therapeutic response
|
|
NZ595290A
(en)
|
2009-03-24 |
2012-09-28 |
Transgene Sa |
Biomarker for monitoring patients
|
|
WO2010119003A1
(en)
|
2009-04-17 |
2010-10-21 |
Transgene Sa |
Biomarker for monitoring patients
|
|
CA2767458A1
(en)
|
2009-07-10 |
2011-01-13 |
Bruce Acres |
Biomarker for selecting patients and related methods
|
|
AU2011285534B2
(en)
|
2010-08-06 |
2015-12-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for prostate cancer and methods for their detection
|
|
US9725494B2
(en)
*
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
|
CA2928199C
(en)
*
|
2013-11-05 |
2025-06-17 |
Bavarian Nordic A/S |
POLYTHERAPY FOR CANCER TREATMENT USING A POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST AND/OR AGONIST OF AN IMMUNE CHECKPOINT INHIBITOR
|
|
DK3142689T3
(da)
|
2014-05-13 |
2021-02-15 |
Bavarian Nordic As |
Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3
|
|
CN106999577B
(zh)
|
2014-07-16 |
2021-12-21 |
特兰斯吉恩股份有限公司 |
溶瘤病毒和免疫检查点调节因子组合
|
|
WO2016128542A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
ES2901468T3
(es)
|
2015-07-31 |
2022-03-22 |
Bavarian Nordic As |
Promotores para mejorar la expresión en poxvirus
|
|
US20190183870A1
(en)
|
2016-01-05 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
WO2017129769A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
US20190134190A1
(en)
|
2016-05-04 |
2019-05-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
US11052139B2
(en)
|
2016-09-28 |
2021-07-06 |
Bavarian Nordic A/S |
Compositions and methods for enhancing the stability of transgenes in poxviruses
|
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
EP3562946B1
(en)
|
2016-12-28 |
2021-11-24 |
Transgene SA |
Oncolytic viruses and therapeutic molecules
|
|
WO2018189382A1
(en)
|
2017-04-14 |
2018-10-18 |
Solstice Biologics, Ltd. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
KR20200003921A
(ko)
|
2017-05-15 |
2020-01-10 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정한 바이러스-함유 조성물
|
|
KR102658198B1
(ko)
|
2017-05-15 |
2024-04-16 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정한 바이러스 함유 조성물
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
KR102754876B1
(ko)
|
2017-08-24 |
2025-01-13 |
버베리안 노딕 에이/에스 |
재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
|
|
WO2019170820A1
(en)
|
2018-03-07 |
2019-09-12 |
Transgene |
Parapoxvirus vectors
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
US12150988B2
(en)
|
2018-09-06 |
2024-11-26 |
Bavarian Nordic A/S |
Storage improved poxvirus compositions
|
|
US20220233607A1
(en)
|
2019-05-29 |
2022-07-28 |
Université De Tours |
Toxoplasma platform for treating cancer
|
|
CN115427458A
(zh)
|
2020-02-28 |
2022-12-02 |
塔拉克治疗公司 |
转谷氨酰胺酶介导的缀合
|
|
US20230114464A1
(en)
|
2020-03-12 |
2023-04-13 |
Bavarian Nordic A/S |
Conditions Improving Poxvirus Stability
|
|
TW202413636A
(zh)
|
2022-08-18 |
2024-04-01 |
法商傳斯堅公司 |
嵌合痘病毒
|